CIDeRGeneral Information:
| Id: | 1,996 (click here to show other Interactions for entry) |
| Diseases: |
Diabetes mellitus, type II
- [OMIM]
Insulin resistance Metabolic syndrome Obesity - [OMIM] |
| Rattus norvegicus | |
| male | |
| obese Zucker rat (fa/fa) | |
| article | |
| Reference: | Munoz MC et al.(2009) Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. J. Hypertens. 27: 2409-2420 [PMID: 19901849] |
Interaction Information:
| Comment | Obese Zucker rats displayed hyperglycemia, hypertriglyceridemia, hyperinsulinemia and hypercholesterolemia and increased systolic blood pressure (SBP) together with decreased activation of insulin signaling through the insulin receptor/insulin receptor substrate-1/phosphatidylinositol 3 kinase/Akt pathway in adipose tissue as well as increased adipocytes size, macrophage infiltration and augmented levels of inflammatory mediators such tumor necrosis factor-alpha, monocyte chemoattractant protein-1 and Ang II. Chronic irbesartan (an Ang II receptor blocker) treatment resulted in an improvement of all alterations. Long-term selective Ang II blockade ameliorates insulin resistance in adipose tissue from a model of metabolic syndrome via a mechanism that could involve the modulation of insulin signaling. |
|
Formal Description Interaction-ID: 15754 |
drug/chemical compound decreases_quantity of gene/protein |
| Drugbank entries | Show/Hide entries for Irbesartan |